Introduction
============

*Actinobacillus pleuropneumoniae* (APP) was first isolated from pig lung in 1957 and initially described as *Haemophilus*-like organism, and is one of the most important respiratory pathogens in pigs ([@B36]; [@B12]). This pathogen causes porcine contagious pleuropneumoniae (PCP), which is a major problem for the pig industry worldwide ([@B12]; [@B25]; [@B11]; [@B37]; [@B20]). To date, 15 different serotypes have been identified and the dominant serotypes are different in the various APP endemic regions of the world ([@B38]; [@B30]; [@B28]; [@B5]).

Control of PCP is still a difficult problem worldwide. This disease has long been the subject of numerous studies encompassing many areas like diagnosis, pathogenesis, vaccination, etc. ([@B23]; [@B41]; [@B9]; [@B56]; [@B32]; [@B52]). Furthermore, studies have found an increasing resistance against antimicrobial agents used in pig pleuropneumonia therapy ([@B1]; [@B3]; [@B54]). Routine use of antibiotics in livestock to boost animal growth has inadvertently selected for pathogen resistance; this is thought to be the primary factor behind the rapid increase of resistant APP strain outbreaks observed on pig farms worldwide. This issue has received an increasing amount of attention in developed countries, as well as developing ones such as China.

Commercial inactivated vaccines against APP are used routinely in the porcine agronomy. Moreover, a number of recombinant antigens of APP were demonstrated to be putative vaccine candidates. Most of the current commercial vaccines against this pathogen are traditional inactivated bacterins, which elicit only partial protection, with decreased mortality but not morbidity rates ([@B33]). Traditionally, inactivated vaccines are developed using one or more serovars, which is (are) selected from the local prevalent strain(s). Often, there are multiple serovars prevalent in one country or district ([@B38]; [@B2]; [@B17]; [@B35]; [@B15]). Because of a lack of cross-protection between different serovars, it is difficult to control PCP effectively using inactivated bacterins ([@B45]). APP virulence factors such as apx toxins, are selected as vaccine candidates and show partial cross-protection among different serovars, which are conserved in APP strains ([@B55]; [@B48]). In addition, other virulent factors like AasP autotransporter protein ([@B41]), pilin ([@B33]) were also studied for their potential as vaccine candidates. A number of *in vivo*-induced (IVI) antigens are up-regulated after infection *in vivo*, which are essential for pathogenesis and survival in host internal environment ([@B47]). Recently, advances in biotechnology have allowed for the development of techniques such as IVI antigen technology (IVIAT; [@B18]), signature-tagged mutagenesis (STM; [@B14]), and selective capture of transcribed sequences (SCOTS; [@B4]). These techniques were proven to be effective in the study of virulence factors.

A number of IVI antigens were identified in our previous studies ([@B57]). To evaluate the potential of IVI antigens as vaccine candidates, six antigens were randomly selected from a list of previously identified IVI antigens. In our previous study, IVIAT was used to screen *in vivo* up-regulation antigens of APP; a number of antigens were identified which were involved in metabolism, replication, transcription regulation, signal transduction, and several function-unknown proteins ([@B57]). Six of these were expressed as His-tagged fusion proteins and screened for their potential as vaccine candidates against App in a murine model.

Materials and Methods {#s1}
=====================

Animals and Ethics Statement
----------------------------

Six to eight week female BALB/c mice (18--22 g) were purchased from Chengdu Dossy Experimental Animal Co., Ltd. The animal experiments were conducted in compliance with the animal protocol approved by the Veterinary Medical College at Sichuan Agricultural University. All procedures performed in this study involving animals were approved by the Institutional Animal Care and Use Committee of Sichuan Agricultural University (Approval Number BK2014-047), Sichuan, China and followed the guidelines of the National Institutes of Health.

Bacterial Strains, Media, and Culture Conditions
------------------------------------------------

Recombinant constructs were made using gene recombination technology. *E. coli* DH5α (TIANGEN, China) was used for cloning of recombinants and *E. coli* BL21 (TIANGEN, China) was used to express the proteins encoded-fragments inserted in the expression vectors pET-28a. *E. coli* strains were cultured in Luria--Bertani (LB) medium with kanamycin (50 μg/mL) as needed. APP strains were cultured in Trypticase Soy Agar (TSA) or Trypicase Soy Broth (TSB) (DIFCO Laboratories, USA) with 10% (v/v) fetal calf serum (FBS; SIJIQING, China) and nicotinamide adenine dinucleotide (NAD; 15 μg/mL) at 37°C. APP L20 (serovar 5b reference strain) was purchased from the China Institute of Veterinary Drug Control (Beijing, China).

Bioinformatics Analysis
-----------------------

Signal peptide cleavage sites of open reading frames (ORFs) were predicted using SignalP 4.1 Server^[1](#fn01){ref-type="fn"}^. Before the research was carried out, the antigenicity of these antigens was calculated using bioinformatics prediction software. To determine the antigenicity of the six selected antigens, the complete amino acid sequences of the proteins were predicted using the Protean program in DNAstar; this analysis was performed based on the Jameson--Wolf mathematical model (**Figure [1](#F1){ref-type="fig"}**). All six selected IVI antigens proved to be highly antigenic, and the results of the prediction are shown in **Figure [1](#F1){ref-type="fig"}**. The antigenic indices of these proteins were more than 1.7, indicating that these IVI antigens are likely highly antigenic.

![**Antigenic properties of the *in vivo*-induced antigens predicted using a bioinformatics approach**.](fmicb-07-01623-g001){#F1}

Construction of Expression Recombinant IVI Antigens
---------------------------------------------------

Gene sequences encoding IVI antigens were searched using NCBI database. Primers for cloning these sequences were designed using Primer Premier 5 software. The details of the primers, sequences, and products of the IVI genes are listed in **Table [1](#T1){ref-type="table"}**. In the primer sequences, the underlined nucleotides mark added restriction sites. APP L20 strain was cultured at 37°C overnight and genome DNA was extracted using genome extraction kit (OMEGA, USA). Using the extracted genome DNA as template, genes of the six IVI antigens were amplified using polymerase chain reaction (PCR). Each amplified gene and vector, pET-28a were both cut by a corresponding restriction enzyme, ligated using T4 DNA ligase (NEB, USA; **Table [1](#T1){ref-type="table"}**) and transformed into *E. coli* DH5α. Each clone was confirmed by DNA sequencing.

###### 

Primers used to amplify and clone *A. pleuropneumoniae* IVI gene sequences.

  Sequence name     Primer   Primer sequence (5′--3′)                                Enzyme      Predicted sizes   Molecular weight (kDa)
  ----------------- -------- ------------------------------------------------------- ----------- ----------------- ------------------------
  galU(0651)        AP1F     5′-CG[GGATCC]{.ul}ATGAAAGTAATTATTCCGGTAGCGG-3′          *Bam*HI     900               32.48
                    AP1R     5′-CCC[AAGCTT]{.ul}ATAACGTTTTAGCTAATTTTTTA-3′           *Hin*dIII                     
  AP-*gal*T(0994)   AP2F     5′-CG[GGATCC]{.ul}ATGAGCCAACAATTTATCCTAAACG-3′          *Bam*HI     1050              40.54
                    AP2R     5′-CCC[AAGCTT]{.ul}CTATTGATTTTTATAGTGAACGCTG-3′         *Hin*dIII                     
  AP-*hfl*X(1962)   AP3F     5′-CG[GGATCC]{.ul}ATGGAATTCCAAACGCTTGCCG-3′             *Bam*HI     760               27.72
                    AP3R     5′-ACGTGTAACAGT[AAGCTT]{.ul}GCTTCGG-3′                  *Hin*dIII                     
  APL_1166          AP4F     5′-CG[GGATCC]{.ul}TTGAAAAAAAGTATTTACGATACCC-3′          *Bam*HI     756               29.31
                    AP4R     5′-CCC[AAGCTT]{.ul}AATTTTTTTTAACTGCCTTAATA-3′           *Hin*dIII                     
  rnhB(0129)        AP5F     5′-CG[GGATCC]{.ul}ATGAGTACAAATTTCATTTATCCTA-3′          *Bam*HI     594               21.42
                    AP5R     5′-CCC[AAGCTT]{.ul}ATAAACCTAAGATTTTCTTCACC-3′           *Hin*dIII                     
  APL_1061          AP6F     5′-CG[GGATCC]{.ul}ACGACCGCACAAGCGCAAAATAACG-3′          *Bam*HI     597               22.19
                    AP6R     5′-ATAAGAAT[GCGGCCGC]{.ul}TATTTCAATCTCGTGATGTTTTTC-3′   *Not*I                        

Expression and Purification of the IVI Recombinant Protein
----------------------------------------------------------

For expression, identified recombinant plasmids were extracted from *E. coli* DH5α and transformed into *E. coli* BL21. Clones were cultured in LB and induced with isopropyl-β-[D]{.smallcaps}-thiogalactoside (IPTG) for 4 h. Recombinant proteins were purified using Ni-chelating affinity chromatography (BIO-RAD, USA). The purified proteins were examined by 12% SDS-PAGE as previously described (**Figure [2](#F2){ref-type="fig"}**).

![**SDS-PAGE of un-induced **(A)** and induced **(B)** recombinant strains.** The expression proteins are marked with blue rectangles.](fmicb-07-01623-g002){#F2}

Western Blotting
----------------

Western blotting was performed as described previously ([@B16]). The membrane was visualized using BeyoECL Star (BEYOTIME, China) and pictures were taken using a ChemiDoc imaging system (BIO-RAD, USA).

Vaccination and Animal Challenge
--------------------------------

To obtain an accurate challenge dose, the LD~50~ was determined using a Reed--Muench method ([@B43]). Animals were divided randomly into seven groups, 15 animals in each group. For the initial vaccination, six groups were immunized subcutaneously with 50 μg rRnhB, rGalU, rGalT, rAPL_1061, rAPL_1166, and rHflX emulsified in the same volume of complete Freund's adjuvant, respectively. The negative control group was immunized with phosphate buffer solution (PBS) emulsified in complete Freund's adjuvant. Two weeks following the initial immunization, the mice were given a booster shot of the same dose of antigens and complete Freund's adjuvant. Before immunization and 2 weeks post-booster, blood samples were obtained by tail bleeding. Two weeks after the booster immunization, all groups of mice were challenged intraperitoneally with a lethal dose of 5 × 10^8^ colony forming unit (CFU) (10 LD50) of App L20. The animals were intensively monitored daily after challenge for the presence and severity of respiratory symptoms and general illness or mortality. All the challenged animals were euthanized; lung tissue was harvested for histopathologic analysis.

Antibody Determination by Indirect ELISA
----------------------------------------

IgG levels of serum from each vaccination group were determined by indirect enzyme-linked immunosorbent assay (ELISA) as described previously with a minor modification ([@B13]). Briefly, the purified proteins were diluted to an identical concentration (w/v; 2.5 μg/mL) in sodium carbonate buffer (PH 9.6). Each well of 96-well microtiter plates (COSTAR, USA) was coated with diluted protein (100 μL) and incubated at 4°C overnight. The plates were incubated with block buffer (BEYOTIME, China) at room temperature (RT) for 1 h then washed three times using washing buffer (300 μL; BEYOTIME, China). Serum samples were diluted (1:100) with primary antibody dilution buffer (BEYOTIME, China), added to the ELISA wells and incubated overnight. The plates were then washed three times. Horseradish peroxidase (HRP)-labeled goat anti-mouse IgG(H+L) was diluted (1:2000) with secondary antibody dilution buffer (BEYOTIME, China) and added (100 μL) onto plates for incubation at RT for 1 h. After washing three times, soluble tetramethylbenzidine (TMB) substrate solution (TIANGEN, China) was added (100 μL), and plates were incubated in the dark at RT for 30 min. The reaction was terminated with 2 M H~2~SO~4~ and absorbance of each well was read at a wavelength of 450 nm in a microplate absorbance reader (BIO-RAD, USA).

Lymphocyte Proliferation Assay
------------------------------

Lymphocyte proliferation was performed with minor modifications as previously described ([@B13]). Firstly, spleens were isolated aseptically and processed by gentle disruption using sterile stainless steel screen and the rubber seal of a disposable syringe. Splenocytes were suspended in Roswell Park Memorial Institute (RPMI) incomplete medium (THERMO, USA). Cell suspensions were first processed using Red Blood Cell Lysis Buffer (SOLARBIO, China) according to manufacturer's instructions. The erythrocyte-free cells were washed three times with Hank's balanced salt solution (HBSS; THERMO, USA) and then resuspended in complete RPMI medium (THERMO, USA). Cell counting was performed and 100 μL of cells were added (1 × 105 cells) into 96-well culture plates (COSTAR, USA). The cells were stimulated with the recombinant proteins (5 μg/well) or concanavalin A (ConA; SIGMA-ALDRICH, USA) and incubated for 72 h at 37°C in a 5% CO~2~ incubator. Lymphoproliferation assays were performed using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) Cell Proliferation Assay Kit (BEYOTIME, China), according to the manufacturer's instructions. MTT solution was added into each well and plates were incubated for another 4 h. Then 100 μL formazan solutions were added to wells and plates were incubated until formazan was dissolved completely. The absorbance was measured at 595 nm using a microplate absorbance reader (BIO-RAD, USA).

Analysis of the Spleen T-cell Subsets
-------------------------------------

Two weeks post-booster, aliquots of the splenocytes prepared as mentioned above were subjected to T cells subset analysis by flow cytometry. Briefly, cell counting was performed and the concentration of the spleen cells was adjusted to 1 × 10^6^ cells/mL. Hundred microliters of cell suspension was transferred to another centrifuge tube, and stained with rat anti-mouse CD3-Fluorescein (FITC), R-phycoerythrin/Cyanine 5 (SPRD) (Southern Biotech, USA), rat anti-mouse CD4-R-phycoerythrin (PE) (Southern Biotech), and rat anti-mouse CD8a-PerCP (Southern Biotech) at 4°C for 15 min in the dark. Stained cells were washed in PBS and were resuspended in 450 μL PBS. Resuspended cells were analyzed for T cell subsets by BD fluorescence activated cell sorting (FACS) Calibur flow cytometer (BD, USA) and the results of analysis were collected.

Detection of Cytokines by ELISA
-------------------------------

To compare the levels of Th1 and Th2 cells subsets before vaccination and booster, cytokines (IFN-γ, IL-2, and IL-4) in splenocyte culture supernatant were determined using an ELISA kit (NEOBIOSCIENCE, China) per manufacturer's instructions.

Histopathology
--------------

Lungs of animals from different groups were isolated and were fixed by immersion in 10% neutral formalin. Immersed tissues were sectioned at 5 μm thickness, and HE-stained for evaluation of histopathology under an Olympus DP71 microscope.

Immunohistochemical Analysis
----------------------------

Immunohistochemical (IHC) method was conducted to analyze neutrophils and macrophages infiltration in tissues from different groups. IHC staining with monoclonal antibodies (MAbs) was carried out on paraffin wax sections obtained from different mouse lung sections. Two MAbs were used: rabbit anti-mouse CD68 for macrophages and rabbit anti-mouse myeloperoxidase (MPO) for neutrophils (Guge Biotech, Wuhan, China). Sections were treated as described ([@B39]). The stained IHC sections were examined in 200 × magnification and taken photos. IHC photos were analyzed by Image-Pro Plus 6.0 software. Integrated optical density (IOD) of each photo was determined as positive index.

Statistical Analyses
--------------------

All data analyses were performed by SPSS 19.0 software using Student's *t*-test for the comparison of the differences between different groups. *P*-values of \< 0.05 were considered as statistically different and were represented with asterisk. *P*-values of \< 0.001 were represented with two asterisks.

Results
=======

Expression of Six Recombinant Proteins
--------------------------------------

The six recombinant genes were confirmed by sequence analysis (data not shown). The recombinant plasmids were successfully transformed into *E. coli* BL21 and the respective proteins were expressed as His-tagged fusion proteins. SDS-PAGE confirmed that all of these fusion proteins were expressed in *E. coli* BL21 with the expected molecular mass (**Figure [2](#F2){ref-type="fig"}**). Fusion proteins were purified using Ni-chelating affinity chromatography and determined by SDS-PAGE (**Figure [3A](#F3){ref-type="fig"}**). Compared with the results of SDS-PAGE for each IVI antigen protein (**Figure [3A](#F3){ref-type="fig"}**), there was a corresponding exposure stripe on the results of western blotting (**Figure [3B](#F3){ref-type="fig"}**). This demonstrated that these proteins would react with corresponding anti-sera.

![**SDS-PAGE and Western blotting. (A)** SDS-PAGE of six recombinant proteins. **(B)** The results of a western blot of six proteins reacted with corresponding mouse anti-sera. Lane M, protein marker; lanes 1--6, RnhB, GalU, GalT, APL_1061, APL_1166, HflX.](fmicb-07-01623-g003){#F3}

Humoral Immune Responses
------------------------

Two weeks after booster immunization, the serum samples of each group were collected and the IgG levels were tested by indirect ELISA. Referring to the results of indirect ELISA (**Figure [4](#F4){ref-type="fig"}**), IgG levels of every group were increased by relatively large margins compared with the serum before immunization. Compared with negative group, IgG levels of each IVI antigen protein group were significantly elevated (*P* \< 0.001).

![**Analysis of levels of IgG.** Serum samples from immunized controls and negative controls were collected before immunization and 2 weeks after booster immunization. Antibody levels were tested using an indirect ELISA coated with the corresponding recombinant proteins. Antibody levels were demonstrated as absorbance at 450 nm.](fmicb-07-01623-g004){#F4}

Cell-Mediated Immune Response
-----------------------------

Upon stimulation with recombinant proteins, except rRnhB group, levels of lymphocyte proliferation of all the proteins in the immune groups were higher than those of the negative control (**Figure [5](#F5){ref-type="fig"}**). Similarly, lymphocyte proliferation of these groups was also detected after the cells stimulated with ConA.

![**Lymphocyte proliferation assay.** Levels of lymphocyte proliferation of each group were detected using an MTT method and the results shown as absorbance at 595 nm. Splenocytes of animals 2 weeks post-immunization were isolated and stimulated with recombinant proteins and con A.](fmicb-07-01623-g005){#F5}

Distribution of CD3+, CD4+, and CD8+ T cells in the spleen cells were evaluated by FACS. Overall trends in the proportion of CD3+ and CD4+ T cells were higher in immunized mice than the control group animals (**Figure [6](#F6){ref-type="fig"}**). In rGalT group, all of CD3+, CD4+, and CD8+ showed the highest levels, which was significantly higher than the control group (*P* \< 0.05).

![**FACS analysis.** The levels of CD3+ **(A)**, CD3+CD4+ **(B)**, and CD3+CD8+ **(C)** T-cell subsets in splenocytes from immunized groups and the negative control group were analyzed by FACS. The average measured percentages of CD3+, CD3+CD4+, and CD3+CD8+ T-cells with representative scatter diagrams of the T-cells subsets detected by flow cytometry method (data not shown). The means with standard deviations were represented as bars graph, and are representatives of the percentages of CD3+, CD3+CD4+, and CD3+CD8+ T-cells of spleens.](fmicb-07-01623-g006){#F6}

On the other hand, the levels of IFN-γ, IL-2 and IL-4 stimulated with recombinant proteins were significantly higher in the vaccinated groups when compared with the control group (*P* \< 0.05; **Figure [7](#F7){ref-type="fig"}**). The levels of IL-4 in response to stimulation with recombinant proteins were higher than the level of IFN-γ and IL-2 (**Figure [7](#F7){ref-type="fig"}**). Except APL_1166 group, levels of IFN-γ of six immunized groups were significantly higher than the control (*P* \< 0.05). With the exception of the HflX group, both levels of IL-2 and IL-4 of five immunized groups were significantly higher than the control group (*P* \< 0.05).

![**The levels of IFN-γ **(A)**, IL-2 **(B)**, and IL-4 **(C)** in cultured spleen cells of mice injected with proteins or negative control were determined by sandwich ELISA**.](fmicb-07-01623-g007){#F7}

Protective Efficiency in Murine Model
-------------------------------------

The results of vaccination and challenge experiments showed that rGalT, rAPL_1166, and rHlfX provided 87.5, 62.5, and 62.5% protection, respectively (**Figure [8](#F8){ref-type="fig"}**). The mortality of mice in the negative control group was 100% after being challenged with APP L20. The rRnhB, rGalU, and rAPL_1061 immunized groups had an identical protection efficiency of 25% within the observation days (**Figure [8](#F8){ref-type="fig"}**). The survival rate of mice challenged with APP strain L20 after vaccination was shown in **Figure [8](#F8){ref-type="fig"}**.

![**Survival rate of mice challenged with APP strain L20 after immunization.** The animals immunized with recombinant vaccine were challenged after 2 weeks of last booster with 5 × 10^8^ CFU (10 LD50) of App L20, intraperitoneally. The animals were monitored for mortality till day 14 post-challenge. Over all there was significant difference in survival of control and vaccinated animals (*P* \< 0.05). The figure shows the post-challenge survival as a representative vaccine evaluation and difference in time period between mortality of control and vaccine group.](fmicb-07-01623-g008){#F8}

Histopathologic Analysis
------------------------

Histopathologic examination showed the infiltration of neutrophils and macrophages in the lung tissues (**Figure [9](#F9){ref-type="fig"}**). Lung tissue of mice in control group was severely damaged and the structures of pulmonary alveoli showed pathological changes (**Figure [9B](#F9){ref-type="fig"}**). Moreover, the lung parenchyma was edematous (**Figure [9B](#F9){ref-type="fig"}**). However, all surviving mice from the immunized groups did not manifest significant pathological damage (**Figure [9](#F9){ref-type="fig"}**). Immunized groups had only moderate inflammation with infiltration of mixed mononuclear cells and neutrophils (**Figures [9C--H](#F9){ref-type="fig"}**).

![**Lung histopathology.** Mice of each group were sacrificed post-challenge and lungs were collected for histopathology. **(A)** Normal control. **(B)** Negative control. **(C--H)** Lungs from mice immunized with RnhB, GalU, GalT, APL_1061, APL_1166, and HflX, respectively. Hematoxylin and Eosin (H&E), magnification 400×. **(A)** Normal control. **(B)** Negative control mouse lung showing increased inflammatory cell infiltration in the perivascular and peribronchial areas. **(C)** Tissue from mice immunized with rRnhB showing a mild inflammatory cell infiltration in the perivascular and peribronchial areas. **(D)** Lung tissue from surviving infected mouse showing significantly reduced infiltration of inflammatory cells.](fmicb-07-01623-g009){#F9}

Immunohistochemical Analysis
----------------------------

Compared with IHC analysis results of normal control, IOD of neutrophils and macrophages in negative control group were significant higher than normal group (*P* \< 0.05; **Figures [10A,B](#F10){ref-type="fig"}**). IOD of neutrophils in all immunized groups except GalU were not significantly different to that of the normal group. Nevertheless, neither IOD of negative control nor all immunized groups were significantly different with normal control (**Figure [10B](#F10){ref-type="fig"}**).

![**Immunohistochemical analysis.** Mice of each group were sacrificed post-challenge and lungs were collected for histopathology. **(A)** Immunohistochemical **(IHC)** analysis for macrophages. **(B)** IHC analysis for neutrophils. **(a)** Normal control. **(b)** Negative control. **(c--h)** Lungs from mice immunized with RnhB, GalU, GalT, APL_1061, APL_1166, and HflX, respectively. **(i)** Statistical analysis of inflammatory cells.](fmicb-07-01623-g010){#F10}

Discussion
==========

*Actinobacillus pleuropneumoniae* is one of the most important bacterial pathogens, which causes PCP ([@B31]). For strategies aimed at controlling this disease, vaccines appear to be the most effective choice. Over the last several years, numerous studies have been performed with the goal of generating APP vaccines with improved protective efficacy rates. Inactivated whole-cell vaccines have been the standard means used to control PCP. These "traditional" vaccines have reduced, to some extent, mortality rates, but have shown little use in curbing morbidity rates. There was no cross-protection for hosts immunized with inactivated vaccine ([@B27]). However, attenuated mutant vaccine candidates have been shown to provide a partial cross-protection and reduced morbidity ([@B53]; [@B34]). So far, DNA vaccines ([@B8]; [@B33]), subunit vaccines ([@B51]; [@B32]), recombinant subunit vaccines ([@B24]; [@B40], [@B41]; [@B49]; [@B46]; [@B48]; [@B42]; [@B31]), ghost vaccine ([@B29]; [@B19]), and live vector vaccine ([@B50]; [@B21]) for APP had been studied.

The current APP vaccines derive primarily from *apx*, omp and other key antigens, all of which are known virulence factors of APP; these vaccines so far have shown to provide partial protection. However, the current battery of APP vaccines does not protect against all APP pathogenic serovars. We have previously applied IVIAT to screen the genome of APP L20 and a number of IVI antigens were identified ([@B57]). Compared with *in vitro* conditions, the levels of transcription of these antigens *in vivo* were up-regulated. Furthermore, these antigens were demonstrated to be conserved in different serovars. We hypothesized that the IVI antigens identified in our previous study were highly antigenic and could provide immune protection against APP. Among these antigens, APL_1061 and APL_1166 are APP antigens of unknown function. RnhB ([@B22]) and HflX ([@B26]) are ribonuclease H and GTP-binding protein, respectively. GalU, UTP-α-[D]{.smallcaps}-glucose-1-phosphate uridylyltransferase is involved in the LPS core biosynthesis ([@B44]), and GalU and GalT are enzymes involved in metabolism of galactose ([@B10]), all essential for the virulence of different bacterial pathogens ([@B7]; [@B6]).

We performed the vaccine trial using these antigens. Our studies indicated that IVI antigens conferred a partial protection in a mouse challenge model. Vaccinated groups showed high level antibody responses. Also, increased level of cytokines was detected in our vaccinated groups. Among these antigens, GalT, APL_1166, and HflX immunized groups showed relatively high levels of immune protection and could be considered as potential vaccine candidates for further study in piglets.

This is the first report to determine whether the IVI antigens could induce an immune response against App challenge in a mouse model. Both humoral and cellular immune responses were induced in the immunized animals using these IVI antigens as vaccine candidates. However, our recombinant IVI proteins could elicit a strong Th2 response. In conclusion, our results showed that IVI proteins can be used as protective antigens against APP in mice and should be considered as promising vaccine candidates for further studies in a piglet model.
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